Abstract
Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
Molecular Pharmacology November 1996, 50 (5) 1057-1064;